Current Report Filing (8-k)
July 19 2021 - 04:49PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT PURSUANT
TO
SECTION 13 or 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of report (Date of earliest event reported): July 14,
2021
Rennova
Health, Inc.
(Exact
Name of Registrant as Specified in Its Charter)
Delaware
(State
or Other Jurisdiction of Incorporation)
001-35141 |
|
68-0370244 |
(Commission
File Number) |
|
(I.R.S.
Employer Identification No.) |
400 S. Australian
Avenue, Suite 800, West Palm Beach, Florida
|
|
33401 |
(Address
of Principal Executive Offices) |
|
(Zip
Code) |
(561)
855-1626 |
(Registrant’s
Telephone Number, Including Area Code) |
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
[ ] |
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425) |
|
|
[ ] |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12) |
|
|
[ ] |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b)) |
|
|
[ ] |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c)) |
Securities
registered under Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol |
|
Name
of each exchange on which registered |
None |
|
None |
|
None |
Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (§230.405 of
this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934
(§240.12b-2 of this chapter).
Emerging
growth company [ ]
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act.
[ ]
Item
5.03. Amendments to Articles of Incorporation or Bylaws; Change in
Fiscal Year.
On
July 14, 2021, Rennova Health, Inc. (the “Company”) filed an
Amendment to its Certificate of Incorporation in order to effect a
1-for-1,000 reverse stock split of the Company’s shares of common
stock effective on July 16, 2021. As previously announced, on June
15, 2021 the holders of a majority of the total voting power of the
Company’s securities approved an amendment to the Company’s
Certificate of Incorporation to effect a reverse split of all of
the Company’s shares of common stock at a specific ratio within a
range from 1-for-50 to 1-for-2,000, and granted authorization to
the Board of Directors to determine in its discretion the specific
ratio and timing of the reverse split on or prior to December 31,
2021. The Board approved the specific ratio and timing on July 8,
2021.
As a
result of the reverse stock split, every 1,000 shares of the
Company’s pre-reverse split common stock have been combined and
reclassified into one share of the Company’s common stock.
Proportionate voting rights and other rights of common stockholders
were not affected by the reverse stock split, other than as a
result of the cash payment for any fractional shares that would
have otherwise been issued. Stockholders who would otherwise hold a
fractional share of common stock will receive a cash payment in
respect of such fraction of a share of common stock. No fractional
shares will be issued in connection with the reverse stock
split.
The
reverse stock split became effective at 5:00 pm, Eastern Time, on
July 16, 2021 and the Company’s common stock continued to trade on
a post-split basis at the open of business on July 19, 2021. The
Company’s post-reverse split common stock has a new CUSIP number,
but the par value and other terms of the common stock were not
affected by the reverse stock split, except that, for the first 20
days after the reverse split, the common stock will trade under the
symbol “RNVAD”. Thereafter, it will trade under our existing symbol
“RNVA”. Prior to the reverse split the Company had approximately 10
billion shares of common stock outstanding, which resulted in
approximately 10 million post-split shares.
All
outstanding preferred shares, stock options, warrants and equity
incentive plans immediately prior to the reverse stock split have
generally been appropriately adjusted by dividing the number of
shares of common stock into which the preferred shares, stock
options, warrants and equity incentive plans are exercisable or
convertible by 1,000 and multiplying the exercise or conversion
price by 1,000, as a result of the reverse stock split.
The
Company’s transfer agent, Computershare Inc., is acting as exchange
agent for the reverse stock split and will send instructions to
stockholders of record regarding the exchange of certificates for
common stock.
Item 9.01.
Financial Statements and Exhibits.
(d)
Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
Date:
July 19, 2021 |
RENNOVA
HEALTH, INC. |
|
|
|
|
By: |
/s/
Seamus Lagan |
|
|
Seamus
Lagan |
|
|
Chief
Executive Officer |
|
|
(principal
executive officer) |
Rennova Health (PK) (USOTC:RNVA)
Historical Stock Chart
From Jul 2022 to Aug 2022
Rennova Health (PK) (USOTC:RNVA)
Historical Stock Chart
From Aug 2021 to Aug 2022